






Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3503	((514/252.18,256) or (544/327,328,329)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/18 10:31
L2	2650225	"2004".py. or "2005".py.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/04/18 10:31
L3	430	1 and 2	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/04/18 10:31



chain nodes :

13 14 15 28 29 31 32 34 35 37

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 19 20 21 22 23 24

ring/chain nodes :

33

chain bonds :

7-15 13-14 13-28 14-15 14-34 29-31 31-32 31-33 34-35 34-37

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 19-20  
19-24 20-21 21-22 22-23 23-24

exact/norm bonds :

13-14 13-28 29-31 31-32 31-33 34-35 34-37

exact bonds :

7-15 14-15 14-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 19-20  
19-24 20-21 21-22 22-23 23-24

isolated ring systems :

containing 1 : 7 : 19 :

G1:[\*1],[\*2]

G2:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 19:Atom 20:Atom  
21:Atom 22:Atom 23:Atom 24:Atom 28:CLASS 29:CLASS 30:CLASS 31:CLASS  
32:CLASS 33:CLASS 34:CLASS 35:CLASS 37:CLASS

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1006 AND 1839


L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10748089.str



chain nodes :

13 14 15 28 29 31 32

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 19 20 21 22 23 24

ring/chain nodes :

33

chain bonds :

7-15 13-14 13-28 14-15 29-31 31-32 31-33

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 19-20 19-24  
20-21 21-22 22-23 23-24

exact/norm bonds :

13-14 13-28 29-31 31-32 31-33

exact bonds :

7-15 14-15

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 19-20 19-24  
20-21 21-22 22-23 23-24

isolated ring systems :

containing 1 : 7 : 19 :

G1:[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 19:Atom 20:Atom 21:Atom 22:Atom  
23:Atom 24:Atom 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d l4

L4 HAS NO ANSWERS

L1 SCR 1006 AND 1839

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s l4 sss sam

SAMPLE SEARCH INITIATED 09:32:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 105 TO ITERATE

100.0% PROCESSED 105 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1486 TO 2714

PROJECTED ANSWERS: 7 TO 298

L5 7 SEA SSS SAM L3 AND L1 NOT L2

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1006 AND 1839

L6 SCREEN CREATED


=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>



Uploading C:\Program Files\Stnexp\Queries\10748089 (a).str



chain nodes :

13 14 15 28 29 31 32 34 35 37

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 19 20 21 22 23 24

ring/chain nodes :

33

chain bonds :

7-15 13-14 13-28 14-15 14-34 29-31 31-32 31-33 34-35 34-37

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 19-20 19-24  
20-21 21-22 22-23 23-24

exact/norm bonds :

13-14 13-28 29-31 31-32 31-33 34-35 34-37

exact bonds :

7-15 14-15 14-34

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 19-20 19-24  
20-21 21-22 22-23 23-24

isolated ring systems :

containing 1 : 7 : 19 :

G1:[\*1],[\*2]

G2:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 19:Atom 20:Atom 21:Atom 22:Atom  
23:Atom 24:Atom 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS  
34:CLASS 35:CLASS 37:CLASS

L8        STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9    QUE L8 AND L6 NOT L7

=>.d 19

L9 HAS NO ANSWERS

L6                SCR 1006 AND 1839

L7                SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L8                STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

L9                QUE L8 AND L6 NOT L7

=> s 19 sss sam

SAMPLE SEARCH INITIATED 09:35:01 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        42 TO ITERATE

100.0% PROCESSED        42 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        452 TO        1228

PROJECTED ANSWERS:            7 TO        298

L10                7 SEA SSS SAM L8 AND L6 NOT L7

=> s 19 sss ful

FULL SEARCH INITIATED 09:35:52 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -        990 TO ITERATE

100.0% PROCESSED        990 ITERATIONS

158 ANSWERS

SEARCH TIME: 00.00.01

L11                158 SEA SSS FUL L8 AND L6 NOT L7

=> => s 111

L12                6 L11

=> d 112 1-6 bib,ab,hitstr

L12 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:14169 CAPLUS  
 DN 142:114470  
 TI Preparation of sulfonylated peptide derivatives for treating rheumatoid arthritis  
 IN Yednock, Theodore A.; Freedman, Stephen B.; Lieberburg, Ivan; Pleiss, Michael A.; Konradi, Andrei W.; Shopp, George; Messersmith, Elizabeth  
 PA Elan Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 736 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.                      KIND                      DATE                      APPLICATION NO.                      DATE

PI WO 2005000246                      A2                      20050106                      WO 2004-US20280                      20040625

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005065192                      A1                      20050324                      US 2004-875282                      20040625  
 US 2005074451                      A1                      20050407                      US 2004-875469                      20040625  
 PRAI US 2003-482211P                      P                      20030625

OS MARPAT 142:114470

AB The invention relates to methods and compns. for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to  $\alpha 4$  integrin or an immunol. active antigen binding fragment in therapeutically effective amts. Compds. R1SO2NR2CHR3-Q-CHR5CO2H [R1 is (un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; R2 can combine with R1 or R3 to form an (un)substituted heterocyclic group; R5 is -(CH2)1-4-Ar-R5', where R5' is -O-Z-NR8R8' or -O-Z-R8'', Ar is (un)substituted aryl or heteroaryl, Z is CO or SO2, R8, R8' are H, (un)substituted alkyl, cycloalkyl or heterocyclyl or NR8R8' is (un)substituted heterocyclyl, and R8'' is (un)substituted heterocyclyl; Q is -C(X)NR7-, where R7 is H or alkyl and X is O or S] are claimed for use in combination therapy. Thus, N-tosyl-L-prolyl-4-(dimethylcarbamoyloxy)-L-phenylalanine Et ester was prepared by acylation of Ts-Pro-Tyr-OEt with dimethylcarbamoyl chloride. Compds. of the invention have binding affinity to  $\alpha 4\beta 1$  (IC50  $\leq 15 \mu\text{M}$ ).

IT 285139-32-4P 285139-33-5P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of sulfonylated peptide derivs. for treating rheumatoid arthritis)

RN 285139-32-4 CAPLUS

CN L-Tyrosine, N-[5-[[[4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-33-5 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 285139-34-6P 285139-40-4P 285139-41-5P  
 285139-42-6P 285139-43-7P 285139-44-8P  
 285139-45-9P 285139-46-0P 285139-47-1P  
 285139-48-2P 285139-50-6P 285139-51-7P  
 285139-53-9P 285139-54-0P 285139-55-1P  
 285139-56-2P 285139-57-3P 285139-58-4P  
 285139-60-8P 285139-62-0P 285139-63-1P  
 285139-64-2P 285139-65-3P 285139-66-4P  
 285139-67-5P 285139-68-6P 285139-69-7P  
 285139-70-0P 285139-71-1P 285139-72-2P  
 285139-73-3P 285139-74-4P 285139-75-5P  
 285139-76-6P 285139-77-7P 285139-78-8P  
 285139-79-9P 285139-80-2P 285139-81-3P  
 285139-82-4P 285139-83-5P 285139-84-6P  
 285139-85-7P 285139-86-8P 285139-87-9P  
 285139-95-9P 285139-96-0P 285139-97-1P  
 285140-23-0P 285140-24-1P  
 285140-25-2P 285140-26-3P 285140-27-4P  
 285140-28-5P 285140-31-0P 285140-33-2P  
 285140-34-3P 285140-35-4P 285140-36-5P

285140-37-6P 285140-39-8P 285140-40-1P  
 285140-41-2P 285140-63-8P 285140-64-9P  
 285140-65-0P 285140-66-1P 285140-67-2P  
 285140-68-3P 285140-75-2P 285140-97-8P  
 630117-86-1P 630117-89-4P 630117-92-9P  
 630117-95-2P 630117-99-6P 630118-01-3P  
 630118-03-5P 630118-06-8P 630118-09-1P  
 630118-12-6P 630118-16-0P 630118-18-2P  
 630118-20-6P 630118-22-8P 630118-23-9P  
 630118-25-1P 630118-27-3P 630118-29-5P  
 630118-30-8P 630118-32-0P 630118-34-2P  
 630118-36-4P 630118-38-6P 630118-40-0P  
 630118-41-1P 630118-43-3P 630118-44-4P  
 630118-46-6P 630118-60-4P 630123-19-2P  
 630123-21-6P 630123-23-8P 630123-25-0P  
 630123-27-2P 630123-29-4P 630123-31-8P  
 630123-33-0P 630123-35-2P 630123-37-4P  
 630123-39-6P 630123-42-1P 630123-44-3P  
 630123-46-5P 630123-48-7P 630123-50-1P  
 630123-52-3P 630123-54-5P 630123-66-9P  
 821800-02-6P 821800-30-0P 821800-31-1P  
 821800-32-2P 821800-33-3P 821800-37-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of sulfonylated peptide derivs. for treating rheumatoid arthritis)

RN 285139-34-6 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-,  
 dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-40-4 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-,  
 dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-41-5 CAPLUS

CN L-Tyrosine, N-[2-[methyl(1-methyl-4-piperidinyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-42-6 CAPLUS

CN L-Tyrosine, N-[2-[ethyl(1-methylethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-43-7 CAPLUS

CN L-Tyrosine, N-[5-(2,4,6-trimethylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-44-8 CAPLUS

CN L-Tyrosine, N-[5-(1-methylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-45-9 CAPLUS

CN L-Tyrosine, N-[2-(butylmethylanino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-46-0 CAPLUS

CN L-Tyrosine, N-[2-(ethylpropylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-47-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 285139-48-2 CAPLUS

CN L-Tyrosine, N-[2-(ethylmethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-50-6 CAPLUS

CN L-Tyrosine, N-[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-51-7 CAPLUS

CN L-Tyrosine, N-(5-phenyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-53-9 CAPLUS

CN L-Tyrosine, N-[5-(2,2,2-trifluoroethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-54-0 CAPLUS

CN L-Tyrosine, N-[5-(phenylmethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-55-1 CAPLUS

CN L-Tyrosine, N-[5-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-56-2 CAPLUS

CN L-Tyrosine, N-[5-[2-(dimethylamino)ethyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-57-3 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(1-methyl-1H-pyrazol-3-yl)sulfonyl]amino]-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-58-4 CAPLUS

CN L-Tyrosine, N-(6-phenyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-60-8 CAPLUS

CN L-Tyrosine, N-[6-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-62-0 CAPLUS

CN L-Tyrosine, N-[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-63-1 CAPLUS

CN L-Tyrosine, N-(5-cyclohexyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-64-2 CAPLUS

CN L-Tyrosine, N-[2-[(2-furanylmethyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-65-3 CAPLUS

CN L-Tyrosine, N-[2-[(4-chlorophenyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-66-4 CAPLUS


CN L-Tyrosine, N-[5-(3-thienyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-67-5 CAPLUS  
 CN L-Tyrosine, N-[5-(2-thienyl)-4-pyrimidinyl]-, dimethylcarbamate (ester)  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-68-6 CAPLUS  
 CN L-Tyrosine, N-[2-[bis(2-hydroxyethyl)amino]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-69-7 CAPLUS  
 CN L-Tyrosine, N-[2-[bis(2-hydroxyethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 285139-70-0 CAPLUS  
 CN L-Tyrosine, N-[5-(2-methylphenyl)-2-(methylphenylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-71-1 CAPLUS

CN L-Tyrosine, N-[2-(1-methylethoxy)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-72-2 CAPLUS

CN L-Tyrosine, N-[2-[methyl(3-methylbutyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-73-3 CAPLUS

CN L-Tyrosine, N-[2-(methylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-74-4 CAPLUS

CN L-Tyrosine, N-[2,5-bis(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 285139-75-5 CAPLUS

CN L-Tyrosine, N-[2-[(2-hydroxyethyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-76-6 CAPLUS

CN L-Tyrosine, N-[2-[methyl(2-methylpropyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-77-7 CAPLUS

CN L-Tyrosine, N-[5-(2-methylphenyl)-2-(methylpropylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-78-8 CAPLUS

CN L-Tyrosine, N-[2-(dimethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-79-9 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-5-(3-pyridinyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-80-2 CAPLUS

CN L-Tyrosine, N-[5-(2,2-difluoro-2-phenylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-81-3 CAPLUS

CN L-Tyrosine, N-[6-chloro-5-(2,2-difluoro-2-phenylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-82-4 CAPLUS

CN L-Tyrosine, N-[5-(2-phenylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-83-5 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-84-6 CAPLUS

CN L-Tyrosine, N-(5-propyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-85-7 CAPLUS

CN L-Tyrosine, N-[5-(2-methoxyphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-86-8 CAPLUS

CN L-Tyrosine, N-[2-[methyl(1-methylethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-87-9 CAPLUS

CN L-Tyrosine, N-[2-[(1-methylethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-95-9 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-96-0 CAPLUS

CN L-Tyrosine, N-[5-(2-methylphenyl)-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-97-1 CAPLUS

CN L-Tyrosine, N-[5-(3-nitrophenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-99-3 CAPLUS

CN L-Tyrosine, N-[5-(2-chloro-5-nitro-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-23-0 CAPLUS

CN L-Tyrosine, N-(2-chloro-5-nitro-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-24-1 CAPLUS

CN L-Tyrosine, N-[5-[[4-methylphenyl]sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-25-2 CAPLUS

CN L-Tyrosine, N-[5-[bis[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285140-26-3 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(1-methyl-1H-pyrazol-4-yl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 285140-27-4 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-28-5 CAPLUS

CN L-Tyrosine, N-[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-31-0 CAPLUS

CN L-Tyrosine, N-[5-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-33-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-methyl-, 4-[(2S)-3-(1-methylethoxy)-2-[[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]amino]-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-34-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-methyl-, 4-[(2S)-3-(1,1-dimethylethoxy)-2-[[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]amino]-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-35-4 CAPLUS

CN L-Tyrosine, N-[5-(2-fluorophenyl)-2-[(2-hydroxyethyl)methylamino]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-36-5 CAPLUS

CN L-Tyrosine, N-[5-(1-piperidiny)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285140-37-6 CAPLUS

CN L-Tyrosine, N-[5-(1-propylbutyl)-4-pyrimidinyl]-, dimethylcarbamate

(ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-39-8 CAPLUS

CN L-Tyrosine, N-[2-(cyclobutylmethylamino)-5-ethyl-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-40-1 CAPLUS

CN L-Tyrosine, N-[5-(2-fluorophenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-41-2 CAPLUS

CN L-Tyrosine, N-[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]-, 4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-63-8 CAPLUS

CN L-Tyrosine, N-[5-[methyl(2-phenylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-64-9 CAPLUS

CN L-Tyrosine, N-[5-(hexylmethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-65-0 CAPLUS

CN L-Tyrosine, N-[5-[methyl(1-methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-66-1 CAPLUS

CN L-Tyrosine, N-[5-[(1,1-dimethylethyl)methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-67-2 CAPLUS

CN L-Tyrosine, N-[5-[ethyl(1-methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-68-3 CAPLUS

CN L-Tyrosine, N-[5-[methyl[2-(4-pyridinyl)ethyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-75-2 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-5-ethyl-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-97-8 CAPLUS

CN L-Tyrosine, N-[5-(2-phenylethyl)-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-86-1 CAPLUS

CN L-Tyrosine, N-[5-[[[4-chlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-89-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[3,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630117-92-9 CAPLUS

CN L-Tyrosine, N-[5-[[[3,4-dichlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 630117-95-2 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[methyl(phenylsulfonyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-99-6 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[(2-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-01-3 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[(3-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-03-5 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl](1-methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-06-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-09-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[3,4-difluorophenyl)sulfonyl](1-

methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-12-6 CAPLUS

CN L-Tyrosine, N-[5-[[[4-chlorophenyl)sulfonyl](1-methylethyl)amino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-16-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[(3,4-difluorophenyl)sulfonyl]ethylamin o]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-18-2 CAPLUS

CN L-Tyrosine, N-[5-[[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-20-6 CAPLUS

CN L-Tyrosine, N-[5-[(cyclopropylmethyl)[(4-fluorophenyl)sulfonyl]amino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-22-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[ (3,5-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-23-9 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[ (3,5-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-25-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[ (2,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-27-3 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[(2,4-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-29-5 CAPLUS

CN L-Tyrosine, N-[5-[(3,5-dichlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-30-8 CAPLUS

CN L-Tyrosine, N-[5-[(3,5-dichlorophenyl)sulfonyl]ethylamino]-2-

(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-32-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]propylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-34-2 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]-2-propenylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-36-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-38-6 CAPLUS

CN L-Tyrosine, N-[5-[butyl[(4-fluorophenyl)sulfonyl]amino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-40-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,6-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 630118-41-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[ (2,3-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-43-3 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[ (4-fluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-44-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-46-6 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-fluorophenyl)sulfonyl](2,2,2-trifluoroethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-60-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester), monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 630123-19-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-21-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-23-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[4-(4-chlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-25-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-27-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-29-4 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-31-8 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-33-0 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-35-2 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-37-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-39-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-42-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-44-3 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630123-46-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[4-fluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 630123-48-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[(2,4-difluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-50-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[(2,4-difluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-52-3 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[4-fluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-54-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]-2-propynylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-66-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 821800-02-6 CAPLUS

CN L-Tyrosine, N-[5-[[[(1-butyl-1H-pyrazol-4-yl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 821800-30-0 CAPLUS

CN L-Tyrosine, N-(2',4'-dimethoxy[5,5'-bipyrimidin]-4-yl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 821800-31-1 CAPLUS

CN L-Tyrosine, N-[5-(2,6-difluorophenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 821800-32-2 CAPLUS

CN L-Tyrosine, N-[5-(phenylmethoxy)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 821800-33-3 CAPLUS

CN L-Tyrosine, N-[2-(cyclobutylmethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 821800-37-7 CAPLUS

CN L-Tyrosine, N-[5-(3-pyridinyl)-4-pyrimidinyl]-, dimethylcarbamate (ester)  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 285139-31-3P 285139-36-8P 630118-53-5P

630118-54-6P 630118-56-8P 630118-58-0P

630118-63-7P 630123-58-9P 630123-60-3P

630123-62-5P 630123-64-7P 630123-68-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of sulfonylated peptide derivs. for treating rheumatoid  
arthritis)

RN 285139-31-3 CAPLUS

CN L-Tyrosine, N-(2-chloro-5-nitro-4-pyrimidinyl)-, 1,1-dimethylethyl ester,  
dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-36-8 CAPLUS

CN L-Tyrosine, N-(5-amino-4-pyrimidinyl)-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-53-5 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-nitro-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-54-6 CAPLUS

CN L-Tyrosine, N-[5-amino-2-(diethylamino)-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-56-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 630118-58-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 630118-63-7 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[(1-methylethyl)amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-58-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[2-(diethylamino)-5-nitro-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-60-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[5-amino-2-(diethylamino)-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 630123-62-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[5-[[4-chlorophenyl)sulfonyl]amino]-2-(diethylamino)-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-64-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[5-[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-68-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-[[2-(diethylamino)-5-nitro-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:14167 CAPLUS  
 DN 142:114469  
 TI Preparation of sulfonylated peptide derivatives for treating rheumatoid arthritis  
 IN Yednock, Theodore A.; Freedman, Stephen B.; Lieberburg, Ivan; Pleiss, Michael A.; Konradi, Andrei W.; Shopp, George; Messersmith, Elizabeth  
 PA Elan Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 647 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000244	A2	20050106	WO 2004-US20240	20040625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065192	A1	20050324	US 2004-875282	20040625
US 2005074451	A1	20050407	US 2004-875469	20040625
PRAI US 2003-482211P	P	20030625		

AB The invention relates to methods and compns. for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to  $\alpha 4$  integrin or an immunol. active antigen binding fragment in therapeutically effective amts. Compds. include those described by formula  $R1SO2NR2CHR3-Q-CHR5CO2H$  [R1 is (un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; R2 can combine with R1 or R3 to form an (un)substituted heterocyclic group; R5 is  $-(CH2)1-4-Ar-R5'$ , where  $R5'$  is  $-O-Z-NR8R8'$  or  $-O-Z-R8''$ , Ar is (un)substituted aryl or heteroaryl, Z is CO or SO2, R8, R8' are H, (un)substituted alkyl, cycloalkyl or heterocyclyl or NR8R8' is (un)substituted heterocyclyl, and R8'' is (un)substituted heterocyclyl; Q is  $-C(X)NR7-$ , where R7 is H or alkyl and X is O or S]. Thus, N-tosyl-L-prolyl-4-(dimethylcarbamoyloxy)-L-phenylalanine Et ester was prepared by acylation of Ts-Pro-Tyr-OEt with dimethylcarbamoyl chloride. Compds. of the invention have binding affinity to  $\alpha 4\beta 1$  (IC50  $\leq 15 \mu M$ ).

IT 285139-32-4P 285139-33-5P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of sulfonylated peptide derivs. for treating rheumatoid arthritis)

RN 285139-32-4 CAPLUS

CN L-Tyrosine, N-[5-[[[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-33-5 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 285139-34-6P 285139-40-4P 285139-41-5P  
 285139-42-6P 285139-43-7P 285139-44-8P  
 285139-45-9P 285139-46-0P 285139-47-1P  
 285139-48-2P 285139-50-6P 285139-51-7P  
 285139-53-9P 285139-54-0P 285139-55-1P  
 285139-56-2P 285139-57-3P 285139-58-4P  
 285139-60-8P 285139-62-0P 285139-63-1P  
 285139-64-2P 285139-65-3P 285139-66-4P  
 285139-67-5P 285139-68-6P 285139-69-7P  
 285139-70-0P 285139-71-1P 285139-72-2P  
 285139-73-3P 285139-74-4P 285139-75-5P  
 285139-76-6P 285139-77-7P 285139-78-8P  
 285139-79-9P 285139-80-2P 285139-81-3P  
 285139-82-4P 285139-83-5P 285139-84-6P  
 285139-85-7P 285139-86-8P 285139-87-9P  
 285139-95-9P 285139-96-0P 285139-97-1P  
 285139-99-3P 285140-97-8P 630117-86-1P  
 630117-89-4P 630117-92-9P 630117-95-2P  
 630117-99-6P 630118-01-3P 630118-03-5P  
 630118-06-8P 630118-09-1P 630118-12-6P  
 630118-16-0P 630118-18-2P 630118-20-6P

630118-22-8P 630118-23-9P 630118-25-1P  
 630118-27-3P 630118-29-5P 630118-30-8P  
 630118-32-0P 630118-34-2P 630118-36-4P  
 630118-38-6P 630118-40-0P 630118-41-1P  
 630118-43-3P 630118-44-4P 630118-46-6P  
 630118-60-4P 630123-19-2P 630123-21-6P  
 630123-23-8P 630123-25-0P 630123-27-2P  
 630123-29-4P 630123-31-8P 630123-33-0P  
 630123-35-2P 630123-37-4P 630123-39-6P  
 630123-42-1P 630123-44-3P 630123-46-5P  
 630123-48-7P 630123-50-1P 630123-52-3P  
 630123-54-5P 630123-66-9P 821800-02-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonylated peptide derivs. for treating rheumatoid arthritis)

RN 285139-34-6 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-40-4 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-41-5 CAPLUS

CN L-Tyrosine, N-[2-[methyl(1-methyl-4-piperidinyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-42-6 CAPLUS

CN L-Tyrosine, N-[2-[ethyl(1-methylethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-43-7 CAPLUS

CN L-Tyrosine, N-[5-(2,4,6-trimethylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-44-8 CAPLUS

CN L-Tyrosine, N-[5-(1-methylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-45-9 CAPLUS

CN L-Tyrosine, N-[2-(butylmethylethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-46-0 CAPLUS

CN L-Tyrosine, N-[2-(ethylpropylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-47-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 285139-48-2 CAPLUS

CN L-Tyrosine, N-[2-(ethylmethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-50-6 CAPLUS

CN L-Tyrosine, N-[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-51-7 CAPLUS

CN L-Tyrosine, N-(5-phenyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-53-9 CAPLUS

CN L-Tyrosine, N-[5-(2,2,2-trifluoroethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-54-0 CAPLUS

CN L-Tyrosine, N-[5-(phenylmethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-55-1 CAPLUS

CN L-Tyrosine, N-[5-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-56-2 CAPLUS

CN L-Tyrosine, N-[5-[2-(dimethylamino)ethyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-57-3 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(1-methyl-1H-pyrazol-3-yl)sulfonyl]amino]-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-58-4 CAPLUS

CN L-Tyrosine, N-(6-phenyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-60-8 CAPLUS

CN L-Tyrosine, N-[6-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-62-0 CAPLUS

CN L-Tyrosine, N-[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]-,  
4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-63-1 CAPLUS

CN L-Tyrosine, N-(5-cyclohexyl-4-pyrimidinyl)-, dimethylcarbamate (ester)  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-64-2 CAPLUS

CN L-Tyrosine, N-[2-[(2-furanylmethyl)methylamino]-5-(2-methylphenyl)-4-  
pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-65-3 CAPLUS

CN L-Tyrosine, N-[2-[(4-chlorophenyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-66-4 CAPLUS


CN L-Tyrosine, N-[5-(3-thienyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-67-5 CAPLUS  
 CN L-Tyrosine, N-[5-(2-thienyl)-4-pyrimidinyl]-, dimethylcarbamate (ester)  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-68-6 CAPLUS  
 CN L-Tyrosine, N-[2-[bis(2-hydroxyethyl)amino]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-69-7 CAPLUS  
 CN L-Tyrosine, N-[2-[bis(2-hydroxyethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 285139-70-0 CAPLUS  
 CN L-Tyrosine, N-[5-(2-methylphenyl)-2-(methylphenylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-71-1 CAPLUS

CN L-Tyrosine, N-[2-(1-methylethoxy)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-72-2 CAPLUS

CN L-Tyrosine, N-[2-[methyl(3-methylbutyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-73-3 CAPLUS

CN L-Tyrosine, N-[2-(methylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-74-4 CAPLUS

CN L-Tyrosine, N-[2,5-bis(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 285139-75-5 CAPLUS

CN L-Tyrosine, N-[2-[(2-hydroxyethyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-76-6 CAPLUS

CN L-Tyrosine, N-[2-[methyl(2-methylpropyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-77-7 CAPLUS

CN L-Tyrosine, N-[5-(2-methylphenyl)-2-(methylpropylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-78-8 CAPLUS

CN L-Tyrosine, N-[2-(dimethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-79-9 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-5-(3-pyridinyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-80-2 CAPLUS

CN L-Tyrosine, N-[5-(2,2-difluoro-2-phenylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-81-3 CAPLUS

CN L-Tyrosine, N-[6-chloro-5-(2,2-difluoro-2-phenylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-82-4 CAPLUS

CN L-Tyrosine, N-[5-(2-phenylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-83-5 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-84-6 CAPLUS

CN L-Tyrosine, N-(5-propyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-85-7 CAPLUS

CN L-Tyrosine, N-[5-(2-methoxyphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-86-8 CAPLUS

CN L-Tyrosine, N-[2-[methyl(1-methylethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-87-9 CAPLUS

CN L-Tyrosine, N-[2-[(1-methylethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-95-9 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-96-0 CAPLUS

CN L-Tyrosine, N-[5-(2-methylphenyl)-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-97-1 CAPLUS

CN L-Tyrosine, N-[5-(3-nitrophenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-99-3 CAPLUS

CN L-Tyrosine, N-[5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-97-8 CAPLUS

CN L-Tyrosine, N-[5-(2-phenylethyl)-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-86-1 CAPLUS

CN L-Tyrosine, N-[5-[[[4-chlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-89-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[3,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630117-92-9 CAPLUS

CN L-Tyrosine, N-[5-[[[3,4-dichlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 630117-95-2 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[methyl(phenylsulfonyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-99-6 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[(2-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-01-3 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[(3-fluorophenyl)sulfonyl]methylamino]-

4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-03-5 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl](1-methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-06-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-09-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[3,4-difluorophenyl)sulfonyl](1-

methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-12-6 CAPLUS

CN L-Tyrosine, N-[5-[[[4-chlorophenyl)sulfonyl](1-methylethyl)amino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-16-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[3,4-difluorophenyl)sulfonyl]ethylamin o]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-18-2 CAPLUS

CN L-Tyrosine, N-[5-[[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-20-6 CAPLUS

CN L-Tyrosine, N-[5-[(cyclopropylmethyl)[(4-fluorophenyl)sulfonyl]amino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-22-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[3,5-difluorophenyl)sulfonyl)methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-23-9 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[3,5-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-25-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl)methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-27-3 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]ethylamin  
o]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-29-5 CAPLUS

CN L-Tyrosine, N-[5-[[3,5-dichlorophenyl)sulfonyl]methylamino]-2-  
(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 630118-30-8 CAPLUS

CN L-Tyrosine, N-[5-[[3,5-dichlorophenyl)sulfonyl]ethylamino]-2-

(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-32-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]propylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-34-2 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]-2-propenylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-36-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-38-6 CAPLUS

CN L-Tyrosine, N-[5-[butyl[(4-fluorophenyl)sulfonyl]amino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-40-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,6-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 630118-41-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,3-difluorophenyl)sulfonyl)methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-43-3 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-fluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-44-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-46-6 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-fluorophenyl)sulfonyl](2,2,2-trifluoroethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-60-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester), monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 630123-19-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-21-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-23-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[4-(4-chlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-25-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-27-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-29-4 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-31-8 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-33-0 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-35-2 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-37-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-39-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-42-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[(2,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-44-3 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[(2,4-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630123-46-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[(4-fluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 630123-48-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-50-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-52-3 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[4-fluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-54-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[4-chlorophenyl)sulfonyl]-2-propynylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-66-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 821800-02-6 CAPLUS

CN L-Tyrosine, N-[5-[[[(1-butyl-1H-pyrazol-4-yl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 285139-31-3P 285139-36-8P 630118-53-5P  
630118-54-6P 630118-56-8P 630118-58-0P  
630118-63-7P 630123-58-9P 630123-60-3P  
630123-62-5P 630123-64-7P 630123-68-1P.


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of sulfonylated peptide derivs. for treating rheumatoid arthritis)

RN 285139-31-3 CAPLUS

CN L-Tyrosine, N-(2-chloro-5-nitro-4-pyrimidinyl)-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-36-8 CAPLUS

CN L-Tyrosine, N-(5-amino-4-pyrimidinyl)-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-53-5 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-nitro-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-54-6 CAPLUS

CN L-Tyrosine, N-[5-amino-2-(diethylamino)-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-56-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 630118-58-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 630118-63-7 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[(1-methylethyl)amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-58-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[2-(diethylamino)-5-nitro-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-60-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[5-amino-2-(diethylamino)-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-62-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[5-[[4-chlorophenyl)sulfonyl]amino]-2-(diethylamino)-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-64-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[5-[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-68-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-[[2-(diethylamino)-5-nitro-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:951018 CAPLUS  
 DN 140:16962  
 TI Preparation of heterocyclic amino acid compounds which inhibit leukocyte adhesion mediated by  $\alpha 4$  integrins  
 IN Konradi, Andrei W.; Semko, Christopher M.; Xu, Ying-Zi; Stappenbeck, Frank; Stupi, Brian P.; Smith, Jenifer; Thorsett, Eugene D.  
 PA Elan Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003099809	A1	20031204	WO 2003-US16804	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481926	AA	20031204	CA 2003-2481926	20030527
US 2004138243	A1	20040715	US 2003-447308	20030527
BR 2003008881	A	20050111	BR 2003-8881	20030527
EP 1507775	A1	20050223	EP 2003-731419	20030527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2002-383020P	P	20020524		
WO 2003-US16804	W	20030527		

OS MARPAT 140:16962

AB Disclosed are pyrimidinyl amino acid derivs. I (X is F, Cl, or Br; p is 0-3; NR1R3 are azetidiny, pyrrolidinyl, pyrrolyl, 2,5-dihydro-1-pyrrolyl, piperidinyl, 1,2,3,6-tetrahydro-1-pyridinyl; R2 is alkyl, alkenyl, or alkylenecycloalkyl) which bind  $\alpha 4$  integrins, preferably VLA-4, inhibit leukocyte adhesion, and are useful in the treatment of inflammatory diseases. Thus, I (NR1R3 = pyrrolyl; R2 = Et; Xp = 4-Cl) was prepared by reaction of tyrosine tert-Bu ester with 2,4-dichloro-5-nitropyrimidine and Et2NH, followed by carbamoylation, catalytic hydrogenation, sulfonylation, N-ethylation, and ester cleavage reactions. The product showed IC50 = 0.011  $\mu\text{g/mL}$  in the fibronectin cell adhesion assay.

IT 630123-17-0P 630123-19-2P 630123-21-6P  
 630123-23-8P 630123-25-0P 630123-27-2P  
 630123-29-4P 630123-31-8P 630123-33-0P  
 630123-35-2P 630123-37-4P 630123-39-6P  
 630123-42-1P 630123-44-3P 630123-46-5P  
 630123-48-7P 630123-50-1P 630123-52-3P  
 630123-54-5P 630123-66-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinyl amino acid compds. which inhibit leukocyte adhesion mediated by  $\alpha 4$  integrins)

RN 630123-17-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-19-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-21-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-23-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-(4-chlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-25-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-27-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-29-4 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-31-8 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[[4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-33-0 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-35-2 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-37-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-39-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-42-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-44-3 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-46-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[4-fluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-48-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-50-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630123-52-3 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[2-(diethylamino)-5-[[4-fluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 630123-54-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]-2-propynylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-66-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-carboxy-2-[[5-[[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]ethyl]phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 630123-64-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidinyl amino acid compds. which inhibit leukocyte adhesion mediated by  $\alpha 4$  integrins)

RN 630123-64-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[5-[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 630123-58-9P 630123-60-3P 630123-62-5P

630123-68-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinyl amino acid compds. which inhibit leukocyte adhesion mediated by  $\alpha 4$  integrins)

RN 630123-58-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[2-(diethylamino)-5-nitro-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-60-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[5-amino-2-(diethylamino)-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 630123-62-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(2S)-2-[[5-[[[4-chlorophenyl]sulfonyl]amino]-2-(diethylamino)-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630123-68-1 CAPLUS

CN 1-Azetidinecarboxylic acid, 4-[(2S)-2-[[2-(diethylamino)-5-nitro-4-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)-3-oxopropyl]phenyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:950802 CAPLUS  
 DN 140:16959  
 TI Preparation of heteroaryl amino acid compounds which inhibit leukocyte adhesion mediated by  $\alpha 4$  integrins  
 IN Konradi, Andrei W.; Semko, Christopher M.; Xu, Ying-Zi; Stappenbeck, Frank; Stupi, Brian P.; Smith, Jenifer; Thorsett, Eugene D.  
 PA Elan Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 77 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003099231	A2	20031204	WO 2003-US17150	20030527
	WO 2003099231	A3	20040122		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IE, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2480756	AA	20031204	CA 2003-2480756	20030527
	US 2004142954	A1	20040722	US 2003-447208	20030527
	EP 1507533	A2	20050223	EP 2003-736768	20030527
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	US 2002-383244P	P	20020524		
	WO 2003-US17150	W	20030527		

OS MARPAT 140:16959

AB Disclosed are pyrimidinyl amino acid derivs. I (X is F, Cl, or Br; p is 0-3; R1 is Me or Et; R2 is alkyl, alkenyl, or alkylencycloalkyl) which bind  $\alpha 4$  integrins, preferably VIA-4, inhibit leukocyte adhesion, and are useful in the treatment of inflammatory diseases. Thus, I (R1 = R2 = Me; Xp = 4-F) was prepared by reaction of 2-amino-3-(4-hydroxyphenyl)propionic acid with 2,4-dichloro-5-nitropyrimidine and Et2NH, followed by dimethylcarbamoylation, catalytic hydrogenation, sulfonylation, N-methylation, and ester cleavage reactions. The product showed IC50 = 0.002  $\mu$ g/mL in the fibronectin cell adhesion assay.

IT 630117-83-8P 630117-86-1P 630117-89-4P  
 630117-92-9P 630117-95-2P 630117-99-6P  
 630118-01-3P 630118-03-5P 630118-06-8P  
 630118-09-1P 630118-12-6P 630118-16-0P  
 630118-18-2P 630118-20-6P 630118-22-8P  
 630118-23-9P 630118-25-1P 630118-27-3P  
 630118-29-5P 630118-30-8P 630118-32-0P  
 630118-34-2P 630118-36-4P 630118-38-6P  
 630118-40-0P 630118-41-1P 630118-43-3P  
 630118-44-4P 630118-46-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrimidinyl amino acid compds. which inhibit leukocyte

adhesion mediated by  $\alpha 4$  integrins)

RN 630117-83-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-86-1 CAPLUS

CN L-Tyrosine, N-[5-[[[4-(4-chlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-89-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[3,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-92-9 CAPLUS

CN L-Tyrosine, N-[5-[[[(3,4-dichlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-95-2 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[methyl(phenylsulfonyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630117-99-6 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[(2-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-01-3 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[ (3-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-03-5 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[ (4-fluorophenyl)sulfonyl] (1-methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-06-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[ethyl[(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 630118-09-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[3,4-difluorophenyl)sulfonyl](1-methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-12-6 CAPLUS

CN L-Tyrosine, N-[5-[[4-chlorophenyl)sulfonyl](1-methylethyl)amino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-16-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[3,4-difluorophenyl)sulfonyl]ethylamin  
o]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-18-2 CAPLUS

CN L-Tyrosine, N-[5-[[[4-chlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-  
pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-20-6 CAPLUS

CN L-Tyrosine, N-[5-[(cyclopropylmethyl)[(4-fluorophenyl)sulfonyl]amino]-2-  
(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 630118-22-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[3,5-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-23-9 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[3,5-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-25-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[(2,4-difluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-27-3 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[(2,4-difluorophenyl)sulfonyl]ethylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-29-5 CAPLUS

CN L-Tyrosine, N-[5-[[[(3,5-dichlorophenyl)sulfonyl]methylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 630118-30-8 CAPLUS

CN L-Tyrosine, N-[5-[[[(3,5-dichlorophenyl)sulfonyl]ethylamino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-32-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[[(4-fluorophenyl)sulfonyl]propylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-34-2 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]-2-propenylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-36-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-38-6 CAPLUS

CN L-Tyrosine, N-[5-[butyl[(4-fluorophenyl)sulfonyl]amino]-2-(diethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-40-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,6-difluorophenyl)sulfonyl)methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-41-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,3-difluorophenyl)sulfonyl)methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-43-3 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-44-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[2,4-difluorophenyl)sulfonyl]-2-propynylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 630118-46-6 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(2,2,2-trifluoroethoxy)phenyl]sulfonyl]pyrimidin-4-yl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 630118-53-5P 630118-54-6P 630118-56-8P  
630118-58-0P 630118-60-4P 630118-63-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidinyl amino acid compds. which inhibit leukocyte adhesion mediated by  $\alpha 4$  integrins)

RN 630118-53-5 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-nitro-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-54-6 CAPLUS

CN L-Tyrosine, N-[5-amino-2-(diethylamino)-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 630118-56-8 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 630118-58-0 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 630118-60-4 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[[4-(4-fluorophenyl)sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester), monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 630118-63-7 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-[(1-methylethyl)amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:513679 CAPLUS

DN 133:120681

TI Preparation of amino acid acyl derivatives as inhibitors of leukocyte adhesion mediated by VLA-4

IN Konradi, Andrei; Pleiss, Michael A.; Thorsett, Eugene D.; Ashwell, Susan; Welmaker, Gregory S.; Kreft, Anthony; Sarantakis, Dimitrios; Dressen, Darren B.; Grant, Francine S.; Semko, Christopher; Xu, Ying-Zi

PA Elan Pharmaceuticals, Inc., USA; American Home Products

SO PCT Int. Appl., 342 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000043372	A1	20000727	WO 2000-US1686	20000121
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2359115	AA	20000727	CA 2000-2359115	20000121
	EP 1144388	A1	20011017	EP 2000-913245	20000121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000007663	A	20020507	BR 2000-7663	20000121
	US 6479492	B1	20021112	US 2000-489378	20000121
	US 6492372	B1	20021210	US 2000-489377	20000121
	AU 773538	B2	20040527	AU 2000-34724	20000121
	ZA 2001005314	A	20030327	ZA 2001-5314	20010627
	NO 2001003600	A	20010920	NO 2001-3600	20010720
	US 2003125324	A1	20030703	US 2002-218366	20020815
	US 2003144328	A1	20030731	US 2002-218445	20020815
	US 2003139402	A1	20030724	US 2002-251442	20020920
	NZ 529822	A	20031219	NZ 2003-529822	20031127
	US 2004147512	A1	20040729	US 2003-748089	20031229
PRAI	US 1999-116923P	A2	19990122		
	US 1999-160999P	P	19991021		
	US 2000-489377	A3	20000121		
	US 2000-489378	A3	20000121		
	WO 2000-US1686	W	20000121		
	US 2002-251442	A1	20020920		

OS MARPAT 133:120681

AB Disclosed are compds. R2-W:CR1-Q-CR3R3'COX and R2-W'-CHR1-Q-CR3R3'COX [R1 and R2 are joined to form a ring; R3, R3' = H, iso-Pr, -CH2Z or :CHZ, where Z = H, acylamino, alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, carboxy, carboxyalkyl, etc.; Q = O, S, SO, SO2, NH or imino group; W = nitrogen, carbon; W' = nitrogen, carbon, oxygen, sulfur, SO, SO2; X = OH, (un)substituted alkoxy, alkenoxy, cycloalkoxy, cycloalkenoxo, aryloxy, heteroaryloxy or heterocyclyloxy, an amino group] which bind VLA-4. Thus, N-[5-(N-4-toluenesulfonylamino)pyrimidin-4-yl]-L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-Bu ester was prepared by condensation of L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-Bu ester with

2,4-dichloro-5-nitropyrimidine, followed by nitro group reduction and tosylation. Compds. synthesized in the examples are expected to have a binding affinity to VLA-4 expressed by an IC50 of 15  $\mu$ M or less.

IT **285139-31-3P 285139-36-8P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino acid acyl derivs. as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 285139-31-3 CAPLUS

CN L-Tyrosine, N-(2-chloro-5-nitro-4-pyrimidinyl)-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-36-8 CAPLUS

CN L-Tyrosine, N-(5-amino-4-pyrimidinyl)-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **285139-32-4P 285139-33-5P**


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of amino acid acyl derivs. as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 285139-32-4 CAPLUS

CN L-Tyrosine, N-[5-[[[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-33-5 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 285139-34-6P 285139-38-0P 285139-40-4P  
 285139-41-5P 285139-42-6P 285139-43-7P  
 285139-44-8P 285139-45-9P 285139-46-0P  
 285139-47-1P 285139-48-2P 285139-50-6P  
 285139-51-7P 285139-53-9P 285139-54-0P  
 285139-55-1P 285139-56-2P 285139-57-3P  
 285139-58-4P 285139-60-8P 285139-62-0P  
 285139-63-1P 285139-64-2P 285139-65-3P  
 285139-66-4P 285139-67-5P 285139-68-6P  
 285139-69-7P 285139-70-0P 285139-71-1P  
 285139-72-2P 285139-73-3P 285139-74-4P  
 285139-75-5P 285139-76-6P 285139-77-7P  
 285139-78-8P 285139-79-9P 285139-80-2P  
 285139-81-3P 285139-82-4P 285139-83-5P  
 285139-84-6P 285139-85-7P 285139-86-8P  
 285139-87-9P 285139-95-9P 285139-96-0P  
 285139-97-1P 285139-99-3P 285140-23-0P  
 285140-24-1P 285140-25-2P 285140-26-3P  
 285140-27-4P 285140-28-5P 285140-29-6P  
 285140-30-9P 285140-31-0P 285140-33-2P  
 285140-34-3P 285140-35-4P 285140-36-5P  
 285140-37-6P 285140-38-7P 285140-39-8P


285140-40-1P 285140-41-2P 285140-63-8P  
 285140-64-9P 285140-65-0P 285140-66-1P  
 285140-67-2P 285140-68-3P 285140-75-2P  
 285140-97-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of amino acid acyl derivs. as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 285139-34-6 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-38-0 CAPLUS

CN L-Tyrosine, N-[5-[[[1-(1,1-dimethylethyl)-1H-pyrazol-4-yl]sulfonyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-40-4 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 285139-41-5 CAPLUS

CN L-Tyrosine, N-[2-[methyl(1-methyl-4-piperidiny)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-42-6 CAPLUS

CN L-Tyrosine, N-[2-[ethyl(1-methylethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-43-7 CAPLUS

CN L-Tyrosine, N-[5-(2,4,6-trimethylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-44-8 CAPLUS

CN L-Tyrosine, N-[5-(1-methylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-45-9 CAPLUS

CN L-Tyrosine, N-[2-(butylmethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-46-0 CAPLUS

CN L-Tyrosine, N-[2-(ethylpropylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-47-1 CAPLUS

CN L-Tyrosine, N-[2-(diethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-48-2 CAPLUS

CN L-Tyrosine, N-[2-(ethylmethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-50-6 CAPLUS

CN L-Tyrosine, N-[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-51-7 CAPLUS

CN L-Tyrosine, N-(5-phenyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-53-9 CAPLUS

CN L-Tyrosine, N-[5-(2,2,2-trifluoroethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-54-0 CAPLUS

CN L-Tyrosine, N-[5-(phenylmethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-55-1 CAPLUS

CN L-Tyrosine, N-[5-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-56-2 CAPLUS

CN L-Tyrosine, N-[5-[2-(dimethylamino)ethyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-57-3 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(1-methyl-1H-pyrazol-3-yl)sulfonyl]amino]-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-58-4 CAPLUS

CN L-Tyrosine, N-(6-phenyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-60-8 CAPLUS

CN L-Tyrosine, N-[6-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-62-0 CAPLUS

CN L-Tyrosine, N-[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]-,  
4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-63-1 CAPLUS

CN L-Tyrosine, N-(5-cyclohexyl-4-pyrimidinyl)-, dimethylcarbamate (ester)  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-64-2 CAPLUS

CN L-Tyrosine, N-[2-[(2-furanylmethyl)methylamino]-5-(2-methylphenyl)-4-  
pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-65-3 CAPLUS

CN L-Tyrosine, N-[2-[(4-chlorophenyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-66-4 CAPLUS

CN L-Tyrosine, N-[5-(3-thienyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 285139-67-5 CAPLUS  
 CN L-Tyrosine, N-[5-(2-thienyl)-4-pyrimidinyl]-, dimethylcarbamate (ester)  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-68-6 CAPLUS  
 CN L-Tyrosine, N-[2-[bis(2-hydroxyethyl)amino]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-69-7 CAPLUS  
 CN L-Tyrosine, N-[2-[bis(2-hydroxyethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 285139-70-0 CAPLUS  
 CN L-Tyrosine, N-[5-(2-methylphenyl)-2-(methylphenylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-71-1 CAPLUS

CN L-Tyrosine, N-[2-(1-methylethoxy)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-72-2 CAPLUS

CN L-Tyrosine, N-[2-[methyl(3-methylbutyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-73-3 CAPLUS

CN L-Tyrosine, N-[2-(methylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-74-4 CAPLUS

CN L-Tyrosine, N-[2,5-bis(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-75-5 CAPLUS

CN L-Tyrosine, N-[2-[(2-hydroxyethyl)methylamino]-5-(2-methylphenyl)-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-76-6 CAPLUS

CN L-Tyrosine, N-[2-[methyl(2-methylpropyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-77-7 CAPLUS

CN L-Tyrosine, N-[5-(2-methylphenyl)-2-(methylpropylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-78-8 CAPLUS

CN L-Tyrosine, N-[2-(dimethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-79-9 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-5-(3-pyridinyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-80-2 CAPLUS

CN L-Tyrosine, N-[5-(2,2-difluoro-2-phenylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-81-3 CAPLUS

CN L-Tyrosine, N-[6-chloro-5-(2,2-difluoro-2-phenylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-82-4 CAPLUS

CN L-Tyrosine, N-[5-(2-phenylethyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-83-5 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-84-6 CAPLUS

CN L-Tyrosine, N-(5-propyl-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-85-7 CAPLUS

CN L-Tyrosine, N-[5-(2-methoxyphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-86-8 CAPLUS

CN L-Tyrosine, N-[2-[methyl(1-methylethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285139-87-9 CAPLUS

CN L-Tyrosine, N-[2-[(1-methylethyl)amino]-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 285139-95-9 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-5-(2-methylphenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-96-0 CAPLUS

CN L-Tyrosine, N-[5-(2-methylphenyl)-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-97-1 CAPLUS

CN L-Tyrosine, N-[5-(3-nitrophenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285139-99-3 CAPLUS

CN L-Tyrosine, N-[5-(2-nitrophenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-23-0 CAPLUS

CN L-Tyrosine, N-(2-chloro-5-nitro-4-pyrimidinyl)-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-24-1 CAPLUS

CN L-Tyrosine, N-[5-[[4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-25-2 CAPLUS

CN L-Tyrosine, N-[5-[bis[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-26-3 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(1-methyl-1H-pyrazol-4-yl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-27-4 CAPLUS

CN L-Tyrosine, N-[5-[methyl[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-28-5 CAPLUS


CN L-Tyrosine, N-[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285140-29-6 CAPLUS  
 CN L-Tyrosine, N-(2,4-dimethoxy-5-pyrimidinyl)-, dimethylcarbamate (ester)  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285140-30-9 CAPLUS  
 CN L-Tyrosine, N-(2,6-difluoro-4-pyrimidinyl)-, dimethylcarbamate (ester)  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285140-31-0 CAPLUS  
 CN L-Tyrosine, N-[5-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 285140-33-2 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-methyl-, 4-[(2S)-3-(1-methylethoxy)-2-[[5-[methyl (3-pyridinylsulfonyl) amino]-4-pyrimidinyl] amino]-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-34-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-methyl-, 4-[(2S)-3-(1,1-dimethylethoxy)-2-[[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]amino]-3-oxopropyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-35-4 CAPLUS

CN L-Tyrosine, N-[5-(2-fluorophenyl)-2-[(2-hydroxyethyl)methylamino]-4-pyrimidinyl]-, 4-(dimethylcarbamate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-36-5 CAPLUS

CN L-Tyrosine, N-[5-(1-piperidiny)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-37-6 CAPLUS

CN L-Tyrosine, N-[5-(1-propylbutyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-38-7 CAPLUS

CN L-Tyrosine, N-[5-(cyclobutylmethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-39-8 CAPLUS

CN L-Tyrosine, N-[2-(cyclobutylmethylamino)-5-ethyl-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-40-1 CAPLUS

CN L-Tyrosine, N-[5-(2-fluorophenyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285140-41-2 CAPLUS

CN L-Tyrosine, N-[5-[methyl(3-pyridinylsulfonyl)amino]-4-pyrimidinyl]-, 4-methyl-1-piperazinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 285140-63-8 CAPLUS

CN L-Tyrosine, N-[5-[methyl(2-phenylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-64-9 CAPLUS

CN L-Tyrosine, N-[5-(hexylmethylamino)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-65-0 CAPLUS

CN L-Tyrosine, N-[5-[methyl(1-methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-66-1 CAPLUS

CN L-Tyrosine, N-[5-[(1,1-dimethylethyl)methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-67-2 CAPLUS

CN L-Tyrosine, N-[5-[ethyl(1-methylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-68-3 CAPLUS

CN L-Tyrosine, N-[5-[methyl[2-(4-pyridinyl)ethyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-75-2 CAPLUS

CN L-Tyrosine, N-[2-(cyclohexylmethylamino)-5-ethyl-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285140-97-8 CAPLUS

CN L-Tyrosine, N-[5-(2-phenylethyl)-4-pyrimidinyl]-, 1-methylethyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:513676 CAPLUS

DN 133:120679

TI Preparation of heterocyclyl amino acid derivatives as inhibitors of leukocyte adhesion mediated by VLA-4

IN Konradi, Andrei W.; Pleiss, Michael A.; Thorsett, Eugene D.; Ashwell, Susan; Sarantakis, Dimitrios; Welmaker, Gregory S.; Kreft, Anthony; Semko, Christopher; Sullivan, Robert Warren; Soares, Christopher Joseph; Ly, Kiev Sui; Tarby, Christine M.

PA Elan Pharmaceuticals, Inc., USA; American Home Products Corporation

SO PCT Int. Appl., 305 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000043369	A1	20000727	WO 2000-US1540	20000121
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2359113	AA	20000727	CA 2000-2359113	20000121
EP 1144384	A1	20011017	EP 2000-904487	20000121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6479492	B1	20021112	US 2000-489378 <sup>*</sup>	20000121
US 6492372	B1	20021210	US 2000-489377 <sup>✓</sup>	20000121
ZA 2001005314	A	20030327	ZA 2001-5314	20010627
US 2003125324	A1	20030703	US 2002-218366 <sup>✗</sup>	20020815
US 2003144328	A1	20030731	US 2002-218445 <sup>✗</sup>	20020815
US 2003139402	A1	20030724	US 2002- <del>251442</del>	20020920
NZ 529822	A	20031219	NZ 2003-529822	20031127
US 2004147512	A1	20040729	US 2003-748089	20031229
PRAI US 1999-116923P	A2	19990122		
US 1999-160999P	P	19991021		
US 2000-489377	A3	20000121		
US 2000-489378	A3	20000121		
WO 2000-US1540	W	20000121		
US 2002-251442	A1	20020920		

OS MARPAT 133:120679

AB Disclosed are compds. R2-W:CR1-Q-CR3R3'COX and R2-W'-CHR1-Q-CR3R3'COX [R1 and R2 are joined to form a ring; R3, R3' = H, iso-Pr, -CH2Z or :CHZ, where Z = H, acylamino, alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, carboxy, carboxyalkyl, etc.; Q = O, S, SO, SO2, NH or imino group; W = nitrogen, carbon; W' = nitrogen, carbon, oxygen, sulfur, SO, SO2; X = OH, (un)substituted alkoxy, alkenoxy, cycloalkoxy, cycloalkenoxo, aryloxy, heteroaryloxy or heterocyclyloxy, an amino group] which bind VLA-4. Thus, N-[6-[N-benzyl-N-(1-phenylethyl)amino]-4-chloro-1,3,5-triazin-2-yl]-L-4-(dimethylcarbamoyloxy)phenylalanine was prepared by condensation of cyanuric chloride with tyrosine O-(dimethylcarbamate) tert-Bu ester and N-benzylphenethylamine, followed by saponification. Compds. synthesized in the examples are expected to have an IC50 of 15  $\mu$ M or less.

IT 285564-49-0P 285564-50-3P 285564-51-4P  
 285564-52-5P 285564-53-6P 285564-54-7P  
 285564-55-8P 285564-56-9P 285564-57-0P  
 285564-58-1P 285564-59-2P 285564-60-5P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclyl amino acid derivs. as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 285564-49-0 CAPLUS

CN L-Tyrosine, N-[6-[[[4-methylphenyl)sulfonyl](2-methylpropyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285564-50-3 CAPLUS

CN L-Tyrosine, N-[6-[methyl[(4-methylphenyl)sulfonyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285564-51-4 CAPLUS

CN L-Tyrosine, N-[6-[(2-phenylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285564-52-5 CAPLUS

CN L-Tyrosine, N-[6-[methyl[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285564-53-6 CAPLUS

CN L-Tyrosine, N-[6-[methyl(phenylmethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285564-54-7 CAPLUS

CN L-Tyrosine, N-[6-(4-acetyl-1-piperazinyl)-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285564-55-8 CAPLUS

CN L-Tyrosine, N-[6-[methyl(3-pyridinylmethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285564-56-9 CAPLUS

CN L-Tyrosine, N-[6-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285564-57-0 CAPLUS

CN L-Tyrosine, N-[6-[methyl(2-phenylethyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 285564-58-1 CAPLUS

CN L-Tyrosine, N-[6-[(2-phenylpropyl)amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 285564-59-2 CAPLUS

CN L-Tyrosine, N-[6-[[2-[(1-methylethyl)amino]-2-oxoethyl]amino]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 285564-60-5 CAPLUS

CN L-Tyrosine, N-[6-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]-4-pyrimidinyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; =&gt; d his

(FILE 'HOME' ENTERED AT 09:32:00 ON 18 APR 2005)

FILE 'REGISTRY' ENTERED AT 09:32:06 ON 18 APR 2005

L1 SCREEN 1006 AND 1839  
 L2 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047  
 L3 STRUCTURE UPLOADED  
 L4 QUE L3 AND L1 NOT L2  
 L5 7 S L4 SSS SAM  
 L6 SCREEN 1006 AND 1839  
 L7 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047  
 L8 STRUCTURE UPLOADED  
 L9 QUE L8 AND L6 NOT L7  
 L10 7 S L9 SSS SAM  
 L11 158 S L9 SSS FUL

FILE 'CAPLUS' ENTERED AT 09:36:00 ON 18 APR 2005

L12 6 S L11

FILE 'CAOLD' ENTERED AT 09:36:50 ON 18 APR 2005

=&gt; s l11

L13 0 L11

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.43	194.64

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-4.38

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 09:37:01 ON 18 APR 2005